Filing Flows › Comparisons › RVMD vs TARS
Revolution Medicines vs Tarsus Pharmaceuticals: RVMD and TARS compared
Revolution Medicines is the larger company: $198M of revenue in its latest quarter (Q3 2026) against $195M for Tarsus Pharmaceuticals (Q3 2026). Revolution Medicines is more profitable, with an operating margin of -188.9% against -340.3%.
Where the money goes: RVMD and TARS
Revolution Medicines (RVMD) · Q3 2026
Revolution Medicines, Q3 2026: revenue $198M, operating margin -188.9%, net loss $407M, operating cash flow −$416M. The chart follows the revenue to costs, profit and cash.
Tarsus Pharmaceuticals (TARS) · Q3 2026
Tarsus Pharmaceuticals, Q3 2026: revenue $195M (+64% year over year), operating margin -340.3%, net loss $668M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Revolution Medicines (RVMD) | Tarsus Pharmaceuticals (TARS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $198M | $195M |
| Revenue growth, Y/Y | — | +64% |
| Operating margin | -188.9% | -340.3% |
| Net earnings | −$407M | −$668M |
| Net margin | -206.2% | -343.5% |
| Operating cash flow | −$416M | −$6.0M |
Questions
Which is bigger, Revolution Medicines or Tarsus Pharmaceuticals?
Revolution Medicines is the larger company: $198M of revenue in its latest quarter (Q3 2026) against $195M for Tarsus Pharmaceuticals (Q3 2026).
Is Revolution Medicines or Tarsus Pharmaceuticals growing faster?
Revolution Medicines is more profitable, with an operating margin of -188.9% against -340.3%.
More: Revolution Medicines earnings · how Revolution Medicines makes money · Tarsus Pharmaceuticals earnings · how Tarsus Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.